Eric Siemers

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials
    Eric Siemers
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Biomark Med 4:81-9. 2010
  2. ncbi Designing clinical trials for early (pre-dementia) Alzheimer's disease: determining the appropriate population for treatment
    E Siemers
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Nutr Health Aging 15:22-4. 2011
  3. ncbi Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers
    Eric Siemers
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Clin Neuropharmacol 28:126-32. 2005
  4. ncbi Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease
    E R Siemers
    Eli Lilly and Company, Indianapolis, IN 46085, USA
    Neurology 66:602-4. 2006
  5. ncbi New pathways in drug discovery for Alzheimer's disease
    Eric R Siemers
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Curr Neurol Neurosci Rep 6:372-8. 2006
  6. ncbi Commentary on "a roadmap for the prevention of dementia: the inaugural Leon Thal Symposium"
    Eric R Siemers
    Eli Lilly and Company, Indianapolis, IN, USA
    Alzheimers Dement 4:171-3. 2008
  7. ncbi Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
    Eric R Siemers
    Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Clin Neuropharmacol 33:67-73. 2010
  8. ncbi Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase
    Eric R Siemers
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285
    Clin Neuropharmacol 30:317-25. 2007
  9. ncbi Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease
    David B Henley
    Eli Lilly and Company, Lilly Corporate Center, Clinical Research Physician, Alzheimer s Team, DC 6161, Indianapolis, IN 46285 6161, USA
    Expert Opin Pharmacother 10:1657-64. 2009
  10. ncbi Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry
    Valentina Gelfanova
    Integrative Biology Division, Lilly Research Laboratories, Greenfield, IN 46140, USA
    Brief Funct Genomic Proteomic 6:149-58. 2007

Collaborators

Detail Information

Publications17

  1. ncbi Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials
    Eric Siemers
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Biomark Med 4:81-9. 2010
    ..Pivotal registration trials that rely on clinical measures as primary end points can utilize biochemical biomarkers as secondary outcomes indirectly measuring Alzheimer's disease pathology...
  2. ncbi Designing clinical trials for early (pre-dementia) Alzheimer's disease: determining the appropriate population for treatment
    E Siemers
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Nutr Health Aging 15:22-4. 2011
    ..While primary prevention based on screening of asymptomatic individuals using biomarkers has broad appeal, secondary prevention employing treatment of patients with MCI may be more easily implemented...
  3. ncbi Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers
    Eric Siemers
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Clin Neuropharmacol 28:126-32. 2005
    ..A dose-dependent reduction in plasma Abeta was demonstrated, and changes in plasma Abeta concentrations were temporally related to the pharmacokinetic characteristics of LY450139...
  4. ncbi Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease
    E R Siemers
    Eli Lilly and Company, Indianapolis, IN 46085, USA
    Neurology 66:602-4. 2006
    ..Abeta(1-40) in plasma decreased by 38.2%; in CSF, Abeta(1-40) decreased by 4.42 +/- 9.55% (p = not significant). Higher drug doses may result in additional decreases in plasma Abeta concentrations and a measurable decrease in CSF Abeta...
  5. ncbi New pathways in drug discovery for Alzheimer's disease
    Eric R Siemers
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Curr Neurol Neurosci Rep 6:372-8. 2006
    ....
  6. ncbi Commentary on "a roadmap for the prevention of dementia: the inaugural Leon Thal Symposium"
    Eric R Siemers
    Eli Lilly and Company, Indianapolis, IN, USA
    Alzheimers Dement 4:171-3. 2008
  7. ncbi Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
    Eric R Siemers
    Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Clin Neuropharmacol 33:67-73. 2010
    ..LY2062430 (solanezumab) is a humanized monoclonal antibody being studied as a putative disease-modifying treatment of AD...
  8. ncbi Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase
    Eric R Siemers
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285
    Clin Neuropharmacol 30:317-25. 2007
    ..gamma-Secretase inhibitors may be useful as disease-modifying drugs for the treatment of Alzheimer disease. LY450139 is a gamma-secretase inhibitor currently in clinical development, with doses being optimized through the use of biomarkers...
  9. ncbi Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease
    David B Henley
    Eli Lilly and Company, Lilly Corporate Center, Clinical Research Physician, Alzheimer s Team, DC 6161, Indianapolis, IN 46285 6161, USA
    Expert Opin Pharmacother 10:1657-64. 2009
    ..Therefore, pharmacological agents that reduce A beta formation may be of therapeutic benefit...
  10. ncbi Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry
    Valentina Gelfanova
    Integrative Biology Division, Lilly Research Laboratories, Greenfield, IN 46140, USA
    Brief Funct Genomic Proteomic 6:149-58. 2007
    ..Application of the MALDI-Tof assay to CSF obtained from healthy volunteers and Alzheimer's disease patients indicated statistically significant 43% lower levels of Abeta(1-42) in the AD group (P = 0.0025)...
  11. ncbi Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab
    Christopher Carlson
    Eli Lilly and Company, Indianapolis, IN, USA
    Alzheimers Dement 7:396-401. 2011
    ..VE may be associated with central nervous system pathology with blood-brain barrier disruptions; however, less is known about the prevalence of naturally occurring VE in patients with Alzheimer's disease (AD)...
  12. ncbi Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease
    Brandy Matthews
    Indiana University School of Medicine, Department of Neurology, Indianapolis, IN, USA
    Am J Geriatr Psychiatry 11:146-59. 2003
    ..An understanding of the relationship between a statistically significant effect size in an imaging marker and a clinically significant change in rate of disease progression will require additional studies...
  13. ncbi Neuropsychological test performance in healthy volunteers before and after donepezil administration
    Leigh J Beglinger
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Psychopharmacol 18:102-8. 2004
    ..While the results are counter to expectations, some tests in the battery did detect a cognitive change (transient mild worsening during drug administration) in healthy volunteers...
  14. ncbi Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model
    Nicolas M Furiak
    Medical Decision Modeling Inc, Indianapolis, IN, USA
    BMC Med Inform Decis Mak 10:24. 2010
    ..Early-stage modeling provides estimates of potential outcomes and informs policy development...
  15. ncbi Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease
    Adam S Fleisher
    University of California, San Diego, La Jolla, CA 92037, USA
    Arch Neurol 65:1031-8. 2008
    ..To evaluate the safety, tolerability, and amyloid beta (Abeta) response to the gamma-secretase inhibitor LY450139 in Alzheimer disease...
  16. ncbi Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry
    Tomoyuki Oe
    Centers for Cancer Pharmacology and Excellence in Environmental Toxicology, Departments of Pharmacology and Chemistry, University of Pennsylvania, Philadelphia, PA 19104-6160, USA
    Rapid Commun Mass Spectrom 20:3723-35. 2006
    ..Moreover, the introduction of stable isotope labeled internal standards offers the potential to achieve a more rigorous account of the influence of methodological effects related to sample collection and processing...
  17. ncbi Partnership between academia and industry for drug discovery in Alzheimer's disease
    Adrian J Ivinson
    Harvard NeuroDiscovery Center, Harvard Medical School, Boston, MA, USA
    Alzheimers Dement 4:80-8. 2008
    ....